Diabetic Peripheral Neuropathy Market Report 2034

DelveInsight’s report, “Diabetic Peripheral Neuropathy Market Insights, Epidemiology, and Market Forecast-2034,” provides a comprehensive analysis of diabetic peripheral neuropathy (DPN). It covers historical and projected epidemiology, along with market trends across major regions including the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan.

To Know in detail about the Diabetic Peripheral Neuropathy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Diabetic Peripheral Neuropathy Market Forecast

Some of the key facts of the Diabetic Peripheral Neuropathy Market Report:

• The Diabetic Peripheral Neuropathy (DPN) market is expected to grow at a notable CAGR over the forecast period of 2020–2034.

• Current treatments for DPN-related pain include antiseizure medications, antidepressants, opioids, and non-opioid pain relievers. Commonly prescribed drugs include LYRICA (Pfizer), NUCYNTA (Assertio Therapeutics, formerly Depomed), CYMBALTA (Eli Lilly), EFFEXOR (Pfizer), and QUTENZA (Averitas), although these therapies are often associated with side effects.

• In 2023, peripheral diabetic neuropathy accounted for the highest number of type-specific diabetic neuropathy cases across the seven major markets (7MM), with approximately 34 million prevalent cases. The United States recorded the largest share, representing nearly 50% of all treated cases, a proportion expected to rise by 2034. Within the EU4 and the UK, Germany reported the most cases, while Spain had the fewest.

• Several promising therapies are in late-stage clinical development, including Engensis (VM202), MEDI7352, and VX-548. In December 2023, Vertex Pharmaceuticals reported positive outcomes from its Phase II dose-ranging trial of suzetrigine (formerly VX-548), an oral selective NaV1.8 pain signal inhibitor. Treatment significantly reduced pain, as measured by the Numeric Pain Rating Scale (NPRS), and was well tolerated across all doses. Vertex plans to initiate a Phase III pivotal trial for suzetrigine in DPN patients in the second half of 2024.

• Key Companies: Helixmith, Aptinyx, WinSanTor, Inc., Regenacy Pharmaceuticals, Novaremed Ltd., Grünenthal GmbH, Glenmark Pharmaceuticals, and others.

• Key Therapies: QUTENZA (capsaicin), TARLIGE (mirogabalin besylate), Engensis (VM202), Suzetrigine (VX-548), among others.

• The DPN market is expected to expand significantly due to rising disease prevalence, growing awareness, and the introduction of multiple late-stage pipeline therapies, which are poised to transform market dynamics over the forecast period.

Diabetic Peripheral Neuropathy Overview

Diabetic Peripheral Neuropathy (DPN) is a form of nerve damage caused by prolonged high blood sugar in individuals with diabetes. It can lead to numbness, reduced sensation, and occasionally pain in the feet, legs, or hands. DPN is the most common diabetes-related complication, affecting approximately 60% to 70% of people with diabetes, though not all experience pain. Importantly, nerve damage is not inevitable—research indicates that maintaining blood glucose levels close to normal can lower the risk of developing DPN.

Diagnosis typically involves a thorough physical examination to evaluate muscle strength, reflexes, and sensory function. Additional assessments, including filament testing, sensory evaluations, nerve conduction studies, electromyography, and autonomic testing, may be used to assess nerve function and muscle response.

The diabetic peripheral neuropathy report provides an in-depth overview of the disease, including its pathophysiology, diagnostic approaches, and treatment options. It also presents a real-world patient journey, tracing the progression from initial symptom onset to diagnosis and comprehensive management.

Get a Free sample for the Diabetic Peripheral Neuropathy Market Forecast, Size & Share Analysis Report

Diabetic Peripheral Neuropathy Epidemiology

The epidemiology section examines past, present, and projected trends in the seven major markets (7MM) from 2020 to 2034. It explores the factors driving these trends through analysis of multiple studies and insights from key opinion leaders. Additionally, the section offers a detailed evaluation of the diagnosed patient population and anticipated future developments.

Diabetic Peripheral Neuropathy Epidemiology Segmentation:

The Diabetic Peripheral Neuropathy market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Diagnosed Prevalence of Diabetic Peripheral Neuropathy in Adults

• Diagnosed Prevalence of Diabetic Peripheral Neuropathy in Pediatrics

• Diagnosed Prevalence of Diabetic Peripheral Neuropathy by Types

• Diagnosed Prevalence of Diabetic Peripheral Neuropathy by Location

• Diagnosed Prevalence of Diabetic Peripheral Neuropathy by Severity

Download the report to understand which factors are driving Diabetic Peripheral Neuropathy epidemiology trends

Diabetic Peripheral Neuropathy Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Diabetic Peripheral Neuropathy market or expected to get launched during the study period. The analysis covers Diabetic Peripheral Neuropathy market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Diabetic Peripheral Neuropathy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Diabetic Peripheral Neuropathy Therapies: QUTENZA (capsaicin), TARLIGE (mirogabalin besylate), Engensis (VM202), Suzetrigine (VX-548), and others

Diabetic Peripheral Neuropathy Key Companies: Helixmith, Aptinyx, WinSanTor, Inc., Regenacy Pharmacuticals, Novaremed Ltd., Grünenthal GmbH, Glenmark Pharmaceuticals, and others

Discover more about therapies set to grab major Diabetic Peripheral Neuropathy market share @ Diabetic Peripheral Neuropathy Treatment Landscape

Diabetic Peripheral Neuropathy Treatment Market

Treatment of diabetic peripheral neuropathy (DPN) emphasizes effective diabetes management alongside symptom relief. The first step is achieving proper glycemic control, which can lower the risk of complications such as falls and foot ulcers. The main pillars of treatment include blood sugar management, appropriate foot care, and pain relief. Commonly used medications for neuropathic pain include Gabapentin, Pregabalin, Tricyclic Antidepressants (TCAs), Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), and opioids, with alternatives like antiseizure drugs such as carbamazepine or lamotrigine also available.

Patients should collaborate closely with their healthcare providers to create individualized treatment plans. Because responses to therapy can vary, regular follow-ups are important to monitor progress and make adjustments as needed. Ongoing diabetes management remains a critical aspect of DPN care.

Several companies, including Helixmith, Vertex Pharmaceuticals, and AstraZeneca, are actively conducting clinical trials to investigate new treatment options for diabetic peripheral neuropathy.

Scope of the Diabetic Peripheral Neuropathy Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Diabetic Peripheral Neuropathy Companies: Helixmith, Aptinyx, WinSanTor, Inc., Regenacy Pharmacuticals, Novaremed Ltd., Grünenthal GmbH, Glenmark Pharmaceuticals, and others

• Key Diabetic Peripheral Neuropathy Therapies: QUTENZA (capsaicin), TARLIGE (mirogabalin besylate), Engensis (VM202), Suzetrigine (VX-548), and others

• Diabetic Peripheral Neuropathy Therapeutic Assessment: Diabetic Peripheral Neuropathy current marketed and Diabetic Peripheral Neuropathy emerging therapies

• Diabetic Peripheral Neuropathy Market Dynamics: Diabetic Peripheral Neuropathy market drivers and Diabetic Peripheral Neuropathy market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Diabetic Peripheral Neuropathy Unmet Needs, KOL’s views, Analyst’s views, Diabetic Peripheral Neuropathy Market Access and Reimbursement

To know more about Diabetic Peripheral Neuropathy companies working in the treatment market, visit @ Diabetic Peripheral Neuropathy Clinical Trials and Therapeutic Assessment

Table of Contents

1. Diabetic Peripheral Neuropathy Market Report Introduction

2. Executive Summary for Diabetic Peripheral Neuropathy

3. SWOT analysis of Diabetic Peripheral Neuropathy

4. Diabetic Peripheral Neuropathy Patient Share (%) Overview at a Glance

5. Diabetic Peripheral Neuropathy Market Overview at a Glance

6. Diabetic Peripheral Neuropathy Disease Background and Overview

7. Diabetic Peripheral Neuropathy Epidemiology and Patient Population

8. Country-Specific Patient Population of Diabetic Peripheral Neuropathy

9. Diabetic Peripheral Neuropathy Current Treatment and Medical Practices

10. Diabetic Peripheral Neuropathy Unmet Needs

11. Diabetic Peripheral Neuropathy Emerging Therapies

12. Diabetic Peripheral Neuropathy Market Outlook

13. Country-Wise Diabetic Peripheral Neuropathy Market Analysis (2020–2034)

14. Diabetic Peripheral Neuropathy Market Access and Reimbursement of Therapies

15. Diabetic Peripheral Neuropathy Market Drivers

16. Diabetic Peripheral Neuropathy Market Barriers

17. Diabetic Peripheral Neuropathy Appendix

18. Diabetic Peripheral Neuropathy Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Related Reports:

Diabetic Peripheral Neuropathy Pipeline

“Diabetic Peripheral Neuropathy Pipeline Insight, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Diabetic Peripheral Neuropathy market. A detailed picture of the Diabetic Peripheral Neuropathy pipeline landscape is provided, which includes the disease overview and Diabetic Peripheral Neuropathy treatment guidelines.

Diabetic Peripheral Neuropathy Epidemiology

DelveInsight’s ‘Diabetic Peripheral Neuropathy Epidemiology Forecast to 2034’ report delivers an in-depth understanding of the disease, historical and forecasted Diabetic Peripheral Neuropathy epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/